MEIP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MEIP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of MEI Pharma is: High Risk: High uncertainty.
For the Biotechnology subindustry, MEI Pharma's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, MEI Pharma's Risk Assessment distribution charts can be found below:
* The bar in red indicates where MEI Pharma's Risk Assessment falls into.
MEI Pharma (NAS:MEIP) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Thank you for viewing the detailed overview of MEI Pharma's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Taheer Datoo | director | 181 BAY STREET, SUITE 4200, TORONTO A6 M5J 2T3 |
James P Flynn | director | 41 HARRIS CT, DANVILLE CA 94526 |
Sujay Kango | director | 1028 CHAMBERS COURT, BRIDGEWATER NJ 08807 |
Richard G Ghalie | officer: Chief Medical Officer | C/O FAVRILLE, INC, 10445 PACIFIC CENTER COURT, SAN DIEGO CA 92121 |
Bruce Ross Winson | 10 percent owner | 5950 BERKSHIRE LANE, SUITE 510, DALLAS TX 75225 |
Anson Funds Management Lp | 10 percent owner | 16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248 |
Anson Management Gp Llc | 10 percent owner | 16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248 |
Anson Advisors Inc. | 10 percent owner | 155 UNIVERSITY AVENUE, SUITE 207, TORONTO A6 M5H 3B7 |
Funicular Funds, Lp | 10 percent owner | 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114 |
Amin Nathoo | 10 percent owner | 155 UNIVERSITY AVENUE, SUITE 207, TORONTO Z4 M5H 3B7 |
Moez Kassam | 10 percent owner | 111 PETER STREET, SUITE 904, TORONTO A6 M5V2H1 |
Justin J. File | officer: CFO and Corporate Secretary | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130 |
Jacob Ma-weaver | 10 percent owner | 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114 |
Cable Car Capital Llc | 10 percent owner | 2261 MARKET STREET #4307, SAN FRANCISCO CA 94114 |
Baltic Charles V. Iii | director | C/O MARSHALL EDWARDS, INC., 11975 EL CAMINO REAL, SUITE 101, SAN DIEGO CA 92130 |
From GuruFocus
By Business Wire • 07-07-2023
By Marketwired • 07-17-2023
By Marketwired • 06-27-2023
By Business Wire • 11-01-2023
By Business Wire • 09-21-2023
By GuruFocus Research • 09-23-2023
By Business Wire • 12-11-2023
By Business Wire • 06-29-2023
By Business Wire • 10-02-2023
By Business Wire • 01-16-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.